Integrin Inhibitors

αvβ1

αvβ3

αvβ5

αvβ6

αvβ8

α5β1

α1β1

α2β1

α4β1

α9β1

αIIbβ3

α4β7

αLβ2

Integrin Inhibitors, Agonists & Antagonists

Product Name	αvβ1	αvβ3	αvβ5	αvβ6	αvβ8	α5β1	α1β1	α2β1	α4β1	α9β1	αIIbβ3	α4β7	αLβ2	Purity
Cilengitide		αvβ3, IC₅₀: 4 nM (αvβ3-Vitronectin interaction^[2]) αvβ3, IC₅₀: 0.61 nM (^[1])	αvβ5, IC₅₀: 79 nM (αvβ5-Vitronectin interaction^[2]) αvβ5, IC₅₀: 8.4 nM (^[1])			α5β1, IC₅₀: 14.9 nM (^[1])								99.80%
Cyclo(-RGDfK)		αvβ3, IC₅₀: 0.94 nM												≥98.0%
Bexotegrast	αvβ1, Kd: 3.4 nM			αvβ6, Kd: 5.7 nM										98.94%
MK-0429	αvβ1, IC₅₀: 1.6 nM (inhibition of fibronectin-binding )	αvβ3, IC₅₀: 2.8 nM (inhibition of vitronectin-binding)	αvβ5, IC₅₀: 0.1 nM (inhibition of vitronectin-binding)	αvβ6, IC₅₀: 0.7 nM (inhibition of LAP-binding)	αvβ8, IC₅₀: 0.5 nM (inhibition of LAP-binding)	α5β1, IC₅₀: 12.2 nM (inhibition of fibronectin-binding)								99.08%
Lifitegrast													αLβ2	99.29%
RGD peptide (GRGDNP)						α5β1								99.63%
Cyclo(Arg-Gly-Asp-D-Phe-Cys)		αvβ3												99.70%
RGD peptide (GRGDNP) (TFA)						α5β1								99.94%
BTT-3033								α2β1, EC₅₀: 130 nM						99.22%
Etrolizumab												α4β7		99.56%
Cyclo(RGDyK) trifluoroacetate		αvβ3, IC₅₀: 20 nM												99.92%
Natalizumab									α4β1					≥99.10%
BIO5192								α2β1, IC₅₀: 1053 nM	α4β1, IC₅₀: 1.8 nM	α9β1, IC₅₀: 138 nM		α4β7, IC₅₀: >500 nM		99.96%
Integrin modulator 1									α4β1, IC₅₀: 9.8 nM					99.44%
Firategrast									α4β1			α4β7		99.62%
TC-I 15							α1β1, IC₅₀: 23.6 (α1β1 μM α1β1, IC₅₀: 24.4 (α1β1 μM	α2β1, IC₅₀: 0.4 (α2β1 μM α2β1, IC₅₀: 26.8 (α2β1 μM						99.80%
TR-14035									α4β1, IC₅₀: 87 nM			α4β7, IC₅₀: 7 nM		98.06%
Cyclo(RGDyK)		αvβ3, IC₅₀: 20 nM												99.76%
Cyclo(-RGDfK) TFA		αvβ3, IC₅₀: 0.94 nM												99.82%
Lifitegrast sodium													αLβ2	99.33%
Volociximab						α5β1, EC₅₀: 0.2 nM
αvβ5 integrin-IN-1			αvβ5, pIC₅₀: 8.2											99.72%
BIO5192 hydrate								α2β1, IC₅₀: 1053 nM	α4β1, IC₅₀: 1.8 nM	α9β1, IC₅₀: 138 nM		α4β7, IC₅₀: >500 nM		99.96%
EMD527040				αvβ6, IC₅₀: 6 nM										99.94%
RO0270608									α4β1			α4β7		98.80%
BIO-1211									α4β1, IC₅₀: 4 nM			α4β7, IC₅₀: 2 μM		99.94%
HSDVHK-NH2		αvβ3, IC₅₀: 2.74 nM												99.28%
Echistatin TFA		αvβ3				α5β1					αIIbβ3			98.05%
Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA		αvβ3												98.59%
BOP sodium									α4β1	α9β1				99.11%
Nesvategrast		αvβ3, IC₅₀: 0.6 nM		αvβ6, IC₅₀: 8 nM	αvβ8, IC₅₀: 13 nM
R-BC154 acetate										α9β1
αvβ6-IN-2				αvβ6, pIC₅₀: 7.8
Levocabastine									α4β1
DOTA-ADIBO TFA				αvβ6
K34c						α5β1
JNJ-26076713		αvβ3, IC₅₀: 2.3 nM	αvβ5, IC₅₀: 6.3 nM
Orbofiban											GPIIb/IIIa
Tadocizumab											GPIIb/IIIa
Orbofiban acetate											GPIIb/IIIa			98.13%
αvβ6-IN-1				αvβ6, pIC₅₀: 8.1
Valategrast hydrochloride									α4β1			α4β7
αvβ6 integrin inhibitor 2				αvβ6, IC₅₀: 96.5 nM
Echistatin		αvβ3				α5β1					αIIbβ3
α4 integrin receptor antagonist 3									α4β1			α4β7

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4